Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Raw Materials (2016 - 2025)

Standard Biotools (LAB) has disclosed Raw Materials for 15 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • Quarterly Raw Materials fell 33.82% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Dec 2025, down 33.82% year-over-year, with the annual reading at $8.6 million for FY2025, 33.82% down from the prior year.
  • Raw Materials for Q4 2025 was $8.6 million at Standard Biotools, down from $12.5 million in the prior quarter.
  • The five-year high for Raw Materials was $50.0 million in Q3 2024, with the low at $8.6 million in Q4 2025.
  • Average Raw Materials over 5 years is $18.2 million, with a median of $12.8 million recorded in 2022.
  • The sharpest move saw Raw Materials soared 192.67% in 2024, then crashed 80.09% in 2025.
  • Over 5 years, Raw Materials stood at $9.3 million in 2021, then surged by 80.48% to $16.9 million in 2022, then dropped by 22.68% to $13.0 million in 2023, then changed by 0.0% to $13.0 million in 2024, then crashed by 33.82% to $8.6 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $8.6 million, $12.5 million, and $9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.